Bob Ruffolo discusses the rhythm of drug development.
Since 2002, Robert Ruffolo has been President, Research & Development, Wyeth Pharmaceuticals, and Senior Vice President of Wyeth (http://www.wyeth.com). Following his postdoctoral fellowship at the National Heart, Lung and Blood Institute, he has worked in the pharmaceutical industry, initially spending 6 years at Lilly and then 16 years at SmithKline Beecham. He joined Wyeth in 2000 as Executive Vice President, Pharmaceutical R&D. Also an Adjunct Professor in the College of Pharmacy at Ohio State University, Bob has published nearly 500 full-length papers and has received many awards more commonly presented to academics, such as the John Jacob Abel award from the American Society of Pharmacology and Experimental Therapeutics (ASPET) in 1998.
Ruffolo
Bob
B
Research & Development, Wyeth Pharmaceuticals, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D002626:Chemistry, Pharmaceutical; D004345:Drug Industry; D006333:Heart Failure / Q000188:drug therapy; D011412:Propanolamines / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000639:trends*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol